Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients, suggesting that small molecule inhibitors of RAD51 may provide a novel class of broad-spectrum therapeutics for difficult-to-treat cancers (Zhu et al., 2013). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.